Frequency and characteristics of adverse events caused by anti-tuberculosis drugs in pulmonary tuberculosis patients with diabetes myelitis
https://doi.org/10.21292/2075-1230-2020-98-2-10-14
Abstract
The objective: to study the frequency and nature of adverse events caused by anti-tuberculosis drugs in pulmonary tuberculosis patients with and without concurrent diabetes mellitus.
Subjects and methods. 396 patients with pulmonary tuberculosis were examined: 203 patients who had diabetes were included in the TB + diabetes group; the TB group consisted of 193 patients with pulmonary tuberculosis without diabetes.
Results. The incidence of adverse events caused by anti-tuberculosis drugs was analyzed and compared in both groups. Thus, in the TB+diabetes group adverse events developed in 146/203 (71.9%) patients and in 62/193 (32.1%) patients in the TB group ( p < 0.01). Hepatotoxic reactions prevailed in both groups, but in the TB + diabetes group, they were statistically significantly more frequent versus the TB group (55.2 and 27.4%, respectively; p < 0.01). Also, allergic reactions (20.7 and 6.2%, respectively; p < 0.01) and neurotoxic events (13.3 and 5.1%, respectively; p < 0.01) were statistically significantly more frequent in the TB + diabetes group compared to the TB group.
About the Authors
O. G. Komissarova
Central Tuberculosis Research Institute,
Pirogov Russian National Research Medical University
Russian Federation
Doctor of Medical Sciences, Deputy Director for Research and Therapy
2, Yauzskaya Alleya, Moscow, 107564
Phone: +7 (499) 785-90-71
Russian Federation
Doctor of Medical Sciences, Deputy Director for Research and Therapy
2, Yauzskaya Alleya, Moscow, 107564
Phone: +7 (499) 785-90-71
R. Yu. Аbdullaev
Central Tuberculosis Research Institute
Russian Federation
Phthisiologist of the 3rd Therapy Department
2, Yauzskaya Alleya, Moscow, 107564
Phone: +7 (499) 785-90-71
Russian Federation
Phthisiologist of the 3rd Therapy Department
2, Yauzskaya Alleya, Moscow, 107564
Phone: +7 (499) 785-90-71
S. V. Aleshina
Central Tuberculosis Research Institute
Russian Federation
Phthisiologist of the 3rd Therapy Department
2, Yauzskaya Alleya, Moscow, 107564
Phone: +7 (499) 785-90-71
Russian Federation
Phthisiologist of the 3rd Therapy Department
2, Yauzskaya Alleya, Moscow, 107564
Phone: +7 (499) 785-90-71
References
1. Dedov I.I., Shestakov M.V., Mayorova A.Yu. Algorithm of special medical care for diabetes patients - issue 9. Sakharniy Diabet, 2019, no. 22(S1), 211p. (In Russ.) https://doi.org/10.14341/DM221S1.
2. Komissarova O.G., Аbdullaev R.Yu., Konyaeva O.O., Mikhaylovskiy А.M. Tuberculosis prevalence, symptoms and treatment efficacy in diabetes patients. Vrach, 2017, vol. 28, no. 2, pp. 24-28. (In Russ.)
3. Komissarova O.G., Аbdullaev R.Yu., Аleshina S.V., Romanov V.V. Complications of diabetes with concurrent pulmonary tuberculosis. Vrach, 2019, vol. 30, no. 7, pp. 38-41. (In Russ.) https://doi.org/ 10.29296/25877305-2019-07-07
4. Jeon C.Y., Murray M.B. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLos Med., 2008, vol. 5, no. 7, pp. e152.
5. Ronacher K., van Crevel R., Critchley J.A. et al. Defining a research agenda to address the converging epidemics of tuberculosis and diabetes: Part 2: Underlying biologic mechanisms. Chest, 2017, vol. 152, no. 1, pp. 174-180.
6. World Health Organization, Global tuberculosis report 2018.WHO/CDS/TB/2018.20. http://www.who.int
Review
For citations:
Komissarova O.G., Аbdullaev R.Yu., Aleshina S.V. Frequency and characteristics of adverse events caused by anti-tuberculosis drugs in pulmonary tuberculosis patients with diabetes myelitis. Tuberculosis and Lung Diseases. 2020;98(2):10-14. (In Russ.) https://doi.org/10.21292/2075-1230-2020-98-2-10-14
Views:
1361
Email this article 